We integrate bioinformatics and high-throughput gene editing technology to create a streamlined workflow for automated cell line production.
CRISPR at the edge of impossible
OXGENE utilises an automated, high-throughput CRISPR engineering platform to meet the ever-increasing demand for custom cell line manufacture and generation of complex disease models.
We’ve optimised our robotic gene editing platform from proprietary guide algorithms to validated product delivery to provide a high-throughput solution for gene knock-outs or complex modifications in multiple cell backgrounds. We offer our partners unparalleled quality and capacity.
Libraries and Screening
OXGENE has developed proprietary CRISPR guide design algorithms for knock-out, knock-in, activation and repression. We couple our design capabilities with high fidelity library construction, tailored to your screen requirements, and provide bespoke plasmid and lentiviral libraries.
We have extensive experience in generating ‘best-in-class’ pooled gRNA libraries ranging from 2,500-100,000 guides, and arrayed libraries in plate format (plasmid and lentivirus) in excess of 1,000 guides. We apply our extensive automation and informatics know-how to facilitate library generation.
In addition to our ‘off-the-shelf’ whole genome library KO and CRISPRa libraries, we offer custom libraries targeting specific gene families and pathways including the kinome, apoptosis, cell cycle, ubiquitin enzymes and the druggable genome.
Our CRISPR screening platform identifies genetic drivers of drug resistance or sensitivity in different disease contexts, and powerfully advances clinical therapy and drug development programs. We work from screen concept and design, through to bioinformatic analysis and validation, giving our customers the time to focus on their crucial research questions.
CRISPR High-throughput/ KO/Complex Modifications
We provide an industry leading, high-throughput, automated, gene editing platform for CRISPR gene knock-out and complex modifications.
We’ve optimised and quality assured each step of our proprietary CRISPR-Cas9 workflow for high throughput engineering. This allows us to systematically address large-scale projects that no-one else can deliver.
This is only the beginning: we’re expanding our capabilities to disease relevant cell lines, stem cell models, and to complex genomic modifications.
We have enjoyed great service from OXGENE...we are excited about working with [them] to further realise our commitment to provide the best quality antibodies in the market using knockout validation, in addition to expanding our edited cell line product portfolio.